相关实验视频

Updated: May 21, 2026

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

基因表达试验可定制HR+/HER2-乳腺癌的辅助内分泌疗法

Michele Bottosso^1,2, Federica Miglietta^1,2, Grazia Maria Vernaci²

¹Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.

Clinical cancer research : an official journal of the American Association for Cancer Research

|April 24, 2024

概括

基因组测定有助于个性化激素受体阳性乳腺癌治疗,通过确定受益于特定内分泌疗法 (ET) 的患者. 这些测试指导治疗持续时间和强度的决定,优化护理和降低毒性.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
翻译研究是翻译研究.

背景情况:

辅助内分泌疗法 (ET) 是激素受体阳性 (HR +) / HER2-乳腺癌的标准.
优化ET需要考虑瘤异质性和减少治疗毒性.
目前的治疗决定在很大程度上依赖于临床病理因素,需要更好的生物标志物.

研究的目的:

审查基因表达试验的证据,以定制HR+/HER2-乳腺癌的辅助ET.
讨论基因组测试在优化ET持续时间和强度方面的作用.
探索使用基因组测试来降低低风险患者的ET升级.

主要方法:

对商业上可用的基因表达试验 (型DX,MammaPrint,BCI,Prosigna,EndoPredict) 的证据的审查.
对基因组测试数据进行分析,以决定延长辅助治疗.
检查ET降级中基因组测试的初步证据.

主要成果:

基因表达试验增强风险分层,并预测HR+/HER2-乳腺癌的治疗反应.
基因组测试显示出优化辅助ET决策的前景,包括延长治疗.
有证据表明,基因组测试可以指导低风险患者的ET降级.

结论:

基因表达试验是个性化HR+/HER2-乳腺癌辅助ET的宝贵工具.
这些基因组工具有助于优化治疗强度和持续时间.
进一步整合基因组测试可以导致更精确,更有效的乳腺癌管理.

更多相关视频

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...